BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27709443)

  • 1. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
    Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
    Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
    Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Windschall D; Müller T; Becker I; Horneff G
    Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
    Windschall D; Müller T; Becker I; Horneff G
    Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.
    Giménez-Roca C; Iglesias E; Torrente-Segarra V; Bou R; Sánchez-Manubens J; Calzada-Hernández J; Hernández S; Ricart S; Antón J
    Rheumatol Int; 2015 Feb; 35(2):323-6. PubMed ID: 25086629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
    Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
    Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
    Brunner HI; Nanda K; Toth M; Foeldvari I; Bohnsack J; Milojevic D; Rabinovich CE; Kingsbury DJ; Marzan K; Chalom E; Horneff G; Kuester RM; Dare JA; Trachana M; Jung LK; Olson J; Minden K; Quartier P; Bereswill M; Kalabic J; Kupper H; Lovell DJ; Martini A; Ruperto N;
    Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1420-1430. PubMed ID: 31421019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis.
    Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G
    Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
    Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
    Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.